Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara ustekinumab in the treatment of moderate to severe Crohns disease CD.Patients were given a 6mgkg intravenous dose followed by a 90mg subcutaneous dose of Jans...
↧